预约演示
更新于：2025-05-16
Terbinafine Hydrochloride
盐酸特比萘芬
更新于：2025-05-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H26ClN |
InChIKeyBWMISRWJRUSYEX-SZKNIZGXSA-N |
CAS号78628-80-5 |
关联
68
项与 盐酸特比萘芬 相关的临床试验TCTR20250319015
Efficacy and Safety of 1% Terbinafine Film-Forming Solution Single Application versus 1% Clotrimazole Cream Standard Dose in the Treatment of Tinea Pedis in Correctional Setting
NCT06400056
Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis
IRCT20240225061105N1
Comparison of the Effect of Terbinafine alone with the Combination of Terbinafine and Prednisolone in the Treatment of Inflammatory Tina Capitis
100 项与 盐酸特比萘芬 相关的临床结果
登录后查看更多信息
100 项与 盐酸特比萘芬 相关的转化医学
登录后查看更多信息
100 项与 盐酸特比萘芬 相关的专利（医药）
登录后查看更多信息
2,710
项与 盐酸特比萘芬 相关的文献（医药）2025-05-04Expert Opinion On Drug Safety
Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
Article
作者: Yang, Xueting ; Shu, Yunfeng ; Tang, Juan ; Kong, Wenqiang ; Wan, Jie
BACKGROUND:
Compartment syndrome is an uncommon but life-threatening condition. No study has comprehensively compared compartment syndrome (CS) association with available drugs. The objective of this study was to estimate the association between CS and drugs using the FDA Adverse Event Report System (FAERS).
RESEARCH DESIGN AND METHODS:
FAERS reports from the first quarter of 2004 to the third quarter of 2023 were analyzed. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify CS cases. Reporting odds ratio (ROR), corresponding to 95% confidence intervals (95% CI) were calculated to detect a positive signal.
RESULTS:
A total of 2197 reports were considered in the study after the inclusion criteria were applied. Totally 100 drugs were found to be associated with CS. The median time for drug-associated CS was 45 days.
CONCLUSIONS:
By analyzing the FAERS database, the study revealed that certain drugs are significantly associated with compartment syndrome. Further studies are needed to verify whether these drugs are associated with such a risk.
2025-05-01CORROSION SCIENCE
A highly effective, economical and environmentally friendly composite corrosion inhibitor strategy for dynamic supercritical CO2
作者: Gao, Zehui ; Li, Jianna ; Lai, Yuekun ; Zhu, Jianbo ; Liu, Chongjun ; Li, Ruidong ; Wang, Yueshe ; Hu, Jun
Supercritical carbon dioxide (sCO2) corrosion remains a significant and ongoing impediment within the domain of carbon capture, utilization, and storage (CCUS) technologies, necessitating the advancement of robust mitigation tactics.Based on exptl. and theor. investigations, we have studied the inhibition performance of a composite formulation on X80 steel.The in-situ electrochem. studies have confirmed the superior performance of this composite inhibitor, achieving an inhibition efficiency exceeding 99.79%.Through atomistic simulations, we gain mechanistic insights at the mol. level, revealing how the dissociated heteroaromatic species of the composite inhibitor effectively chelate to the metal surface through unsaturated oxygen-carbon pairings, thereby enhancing surface coverage.Such findings provide a prototypical structure-activity relation to inform the application of optimized corrosion inhibitor formulations in the challenging setting of sCO2 environments.
2025-05-01JOURNAL OF BASIC MICROBIOLOGY
Autophagy Activated by Atg1 Interacts With Atg9 Promotes Biofilm Formation and Resistance of Candida albicans
Article
作者: Wei, Xin ; Liu, Siqi ; Chen, Xueyi ; Yu, Shenjun ; Huang, Yun ; Zhao, Xiao
ABSTRACT:
Autophagy regulates the development of Candida albicans (C. albicans) biofilms and their sensitivity to antifungals. Atg1, a serine/threonine protein kinase, recruits autophagy‐related proteins for autophagosome formation. Atg9, the only transmembrane protein, is phosphorylated by Atg1 during autophagy. The specific roles of Atg1 and Atg9 in biofilm formation and resistance of C. albicans remain unclear. The study used RT‐qPCR and Western blotting to assess the correlation between Atg1, Atg9 and biofilm formation, XTT reduction assays to evaluate biofilm formation and antifungal resistance, commercial kits to detect reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and autophagy activity, transmission electron microscopy (TEM) to study the morphological changes, protein–protein interaction (PPI) analysis to analyze the interaction between Atg1 and Atg9. Results demonstrated that Atg1 and Atg9 were highly expressed in biofilms than planktonic cells. Biofilm formation, antifungal resistance, MMP and autophagy activity decreased and ROS increased in atg1Δ/Δ and atg9Δ/Δ. TORC1 inhibition with rapamycin rescued the reduced biofilm formation of atg1Δ/Δ and increased antifungal resistance of atg1Δ/Δ and atg9Δ/Δ. PPI analysis and TEM observation indicated that Atg1 interacted with Atg9, which was certified by RT‐qPCR and Western blotting. This study suggested that Atg1 interacts with Atg9, activates the autophagy regulating the formation and sensitivity of C. albicans biofilms.
100 项与 盐酸特比萘芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲癣 | 澳大利亚 | 2003-12-22 | |
| 体癣 | 澳大利亚 | 2003-12-22 | |
| 股癣 | 澳大利亚 | 2003-12-22 | |
| 足癣 | 美国 | 1999-03-09 | |
| 皮肤真菌病 | 中国 | 1997-01-01 | |
| 皮肤念珠菌病 | 日本 | 1993-07-02 | |
| 真菌病 | 日本 | 1993-07-02 | |
| 癣 | 日本 | 1993-07-02 | |
| 花斑癣 | 日本 | 1993-07-02 | |
| 头癣 | 美国 | 1992-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 红斑 | 临床1期 | 美国 | 2017-10-15 | |
| 粘膜念珠菌病 | 临床阶段不明 | 美国 | 2001-08-31 | |
| 口腔念珠菌病 | 临床阶段不明 | 美国 | 2001-08-31 | |
| HIV感染 | 临床阶段不明 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 384 | 網鹹膚鏇顧鹽繭壓襯艱(夢壓窪繭廠顧選鑰糧選) = 鹽鑰製繭範積艱艱膚壓 觸齋鏇蓋壓鏇積窪鬱築 (壓鹽鹹夢鏇淵夢顧廠襯 ) 更多 | 不佳 | 2025-01-10 | |||
临床1期 | 20 | 齋選觸簾顧獵憲糧製廠(鏇繭積糧憲製艱範憲餘) = Adverse events (five patients), such as headache (n = 3), seasonal allergy (n = 1), and neck pain (n = 1), were considered unrelated to MOB015B; no application site reactions or study discontinuations due to an adverse event were observed. 範齋淵膚餘蓋觸齋鏇選 (鑰選艱餘繭網網鬱遞鏇 ) | 积极 | 2024-08-19 | |||
临床3期 | - | 築膚鑰憲觸簾顧糧淵鹹(窪遞醖蓋壓淵願醖廠網) = 膚壓簾觸構壓選廠選觸 簾鏇艱願獵醖願蓋構積 (願築窪餘遞窪鬱網鏇壓 ) 更多 | 非优 | 2021-07-01 | |||
vehicle | 築膚鑰憲觸簾顧糧淵鹹(窪遞醖蓋壓淵願醖廠網) = 鹽築衊顧鹽製簾廠鏇衊 簾鏇艱願獵醖願蓋構積 (願築窪餘遞窪鬱網鏇壓 ) 更多 | ||||||
临床3期 | 452 | 衊蓋醖獵鬱構糧艱窪顧(憲齋壓襯憲糧簾簾餘構) = 廠鏇糧簾廠餘積鹽鏇網 鹽醖簾膚顧衊鏇憲艱範 (齋鹹鏇築製憲淵範獵顧 ) 更多 | 非劣 | 2020-06-25 | |||
衊蓋醖獵鬱構糧艱窪顧(憲齋壓襯憲糧簾簾餘構) = 淵鹽淵範齋簾積鏇鑰鹹 鹽醖簾膚顧衊鏇憲艱範 (齋鹹鏇築製憲淵範獵顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用